Views & Analysis | Perspectives on pharma industry issues

Market Access

What rare disease commercialisation in Europe teaches us - a...

Rare disease launches are the ultimate stress test for European commercialisation.

R&D

Agentic AI and the human element: Building trustworthy autom...

The future of clinical trials isn’t about replacing people. It’s about empowering them with smarter tools.

Oncology

Sponsored

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

R&D

Hexagonal rendering of AI concept on dark blue background

Results, reality, and recalibration: Unpacking AI hype at SC...

SCOPE 2026 was dominated by one big topic: AI. You couldn’t walk five steps without hearing about something that AI was going to fix.

Digital

AI scientists and the robotic labs of tomorrow

AI scientists will no longer operate at the margins of life sciences research - they'll become essential collaborators in the labs of tomorrow.

R&D

The future of patient registries: Leveraging technology for ...

The healthcare industry has a growing need for real world evidence (RWE) and the capture of holistic longitudinal outcomes.

Market Access

Sponsored

12 Questions with Patrick Oliver

Patrick Oliver, General Manager of Alfasigma UK and Ireland, brings 36 years of industry expertise to the role.

Market Access

Money vs mindset: How the NHS can make the most of extra inv...

It was the day we’d all been waiting for. Rachel Reeves’ Autumn Budget felt like it had been on the horizon for a while.

Sales & Marketing

virtual electronic medical record interface

Sponsored

5 forces reshaping pharma commercialisation in 2026

As infrastructure bottlenecks ease and regulatory frameworks mature, pharma's AI adoption is shifting from proof-of-concept to production-grade deployment

Sales & Marketing

Swiss train speeding across bridge against landscape background

A fast start to 2026 signals continued investor confidence i...

Key factors in Switzerland’s success that could make other European life sciences hubs more attractive to investors.

Digital

AI scientists and the robotic labs of tomorrow

AI scientists will no longer operate at the margins of life sciences research - they'll become essential collaborators in the labs of tomorrow.

Digital

On digital health and the Rural Health Transformation Progra...

As reported in January this year, the United States Centers for Medicare & Medicaid Services (CMS) rolled out $10 billion in

Market Access

What rare disease commercialisation in Europe teaches us - a...

Rare disease launches are the ultimate stress test for European commercialisation.

Market Access

Biotech leaders: ‘They're shoving this industry into the arm...

At the Biotech Showcase during JPM Week, biotech leaders expressed frustration at the US's lack of concern about Chinese biotech progress.

Oncology

Sponsored

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

Oncology